MedTrace Logo

DERM NMSC Validation Study

NCT04116983 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 572

Last updated 2022-05-18

No results posted yet for this study

Summary

This study aims to establish the effectiveness of an Artificial Intelligence (AI) algorithm (DERM) to determine the presence of Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) and frequently observed benign conditions, when used to analyse images of skin lesions taken by commonly available smart phone cameras.

Conditions

  • Non-melanoma Skin Cancer

Interventions

DEVICE

Deep Ensemble for the Recognition of Malignancy (DERM)

An AI-based diagnosis support tool

Sponsors & Collaborators

  • Innovate UK

    collaborator OTHER_GOV

  • Skin Analytics Limited

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-26
Primary Completion
2022-02-28
Completion
2022-03-16

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04116983 on ClinicalTrials.gov